Stockreport

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

argenx SE - American Depositary Shares  (ARGX) 
PDF Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in [Read more]